Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Oslo University Hospital.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Mona-Elisabeth Revheim, Oslo University Hospital Identifier:
First received: January 12, 2011
Last updated: October 12, 2012
Last verified: October 2012

The purpose of this study is to compare sensitivity, specificity and accuracy of PET, DW MRI and CT separately and combined for the evaluation of treatment response and progression-free survival in patients with GIST.

Soft Tissue Neoplasms
Gastrointestinal Tract

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI

Resource links provided by NLM:

Further study details as provided by Oslo University Hospital:

Estimated Enrollment: 40
Study Start Date: February 2011

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

GIST patients suitable for medical treatment with targeted therapies.


Inclusion Criteria:

  • Metastatic GIST patients suitable for TKI treatment
  • GIST patients pursuing preoperative neoadjuvant TKI treatment

Exclusion Criteria:

  • Patients with contraindications to MRI and/or TKI treatment. For patients with renal failure, CT without intravenous contrast will be performed according to clinical practice.
  • Patients who do not sign the consent paper for any reason or do not accept the study premises or patients who wish to withdraw for any reason during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01276483

Contact: Mona-Elisabeth Revheim, MD +4723070840
Contact: Therese Seierstad, PhD +4722781237

Oslo University Hosptal Recruiting
Oslo, Norway, 0424
Principal Investigator: Mona-Elisabeth Revheim, MD         
Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Mona-Elisabeth Revheim, MD Oslo University Hospital, Dept of Nuclear Medicine
Study Chair: Therese Seierstad, PhD Oslo University Hospital, Institute for Cancer Research
Principal Investigator: Øyvind S Bruland, Prof., MD Oslo University Hospital, Dept of Oncology, The Norwegian Radium Hospital
Principal Investigator: Knut Håkon Hole, MD Oslo University Hospital, Department of Diagnostic Radiology
Principal Investigator: Lars Julsrud, MD Oslo University Hospital, Department of Diagnostic Radiology
  More Information

No publications provided by Oslo University Hospital

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mona-Elisabeth Revheim, Nuclear Medicine Phycisian, Oslo University Hospital Identifier: NCT01276483     History of Changes
Other Study ID Numbers: REK-2010/2089
Study First Received: January 12, 2011
Last Updated: October 12, 2012
Health Authority: Norway:National Committee for Medical and Health Research Ethics
Norway: Institutional Scientific Board

Keywords provided by Oslo University Hospital:
Response Monitoring
Functional Magnetic Imaging
Positron Emission Tomography
Computer Tomography

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Soft Tissue Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue processed this record on November 25, 2014